Ottawa Hospital Research Institute
ohri.caLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
539
Active
93
Phase 3
51
Total enrollment
2,824,401
Pipeline matrix
Showing 40 of 55 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Apixaban | — | — | — | — | 5 | ||
| Methoxyflurane | — | — | — | — | — | 3 | |
| Cephalexin | — | — | — | — | 3 | ||
| Rivaroxaban | — | — | — | — | — | 3 | |
| Amlodipine | — | — | — | — | 2 | ||
| Spironolactone | — | — | — | — | — | 1 | |
| Candesartan 8mg | — | — | — | — | — | 1 | |
| Hydrochlorothiazide (HCTZ) 25 milligrams. | — | — | — | — | — | 1 | |
| Standard of care administration of Endocrine therapy | — | — | — | — | — | 1 | |
| Dose-frequency escalation administration of Endocrine therapy | — | — | — | — | — | 1 | |
| Granulocyte Colony-Stimulating Factor | — | — | — | — | — | 1 | |
| Omission of Granulocyte Colony-Stimulating Factor | — | — | — | — | — | 1 | |
| 20-25% Albumin fluid | — | — | — | — | — | 1 | |
| Neomycin and Flagyl | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 | |
| Bone modifying agent | — | — | — | — | — | 1 | |
| Rivaroxaban 10 MG | — | — | — | — | — | 3 | |
| Tranexamic Acid | — | — | — | — | 4 | ||
| Prednisone | — | — | — | — | 4 | ||
| Lupron Depot | — | — | — | — | — | 1 | |
| Omeprazole 20 mg Oral | — | — | — | — | — | 1 | |
| The investigational product specifically targeting P. aeruginosa (DP-QB-PSA-005) and that targeting S. aureus (DP-QB-STA-005), each formed of a mixture of 5 bacteriophages. | — | — | — | — | — | 1 | |
| enteric-coated naproxen | — | — | — | — | — | 1 | |
| Rosuvastatin Calcium | — | — | — | — | — | 1 | |
| Colchicine 0.5 mg po | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Standard of Care | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| Full dose rivaroxaban | — | — | — | — | — | 1 | |
| Low dose rivaroxaban | — | — | — | — | — | 1 | |
| Cold-stored platelet concentrate | — | — | — | — | — | 1 | |
| Hydroxychloroquine | — | — | — | — | — | 1 | |
| CLIC-1901 | — | — | — | — | — | 1 | |
| Allogeneic umbilical cord-derived human mesenchymal stromal cells | — | — | — | — | — | 1 | |
| Human Allogenic Umbilical Cord Mesenchymal Stromal Cells | — | — | — | — | — | 1 | |
| Plasma-Lyte A and 25% Autologous Plasma | — | — | — | — | — | 1 | |
| Autologous EPCs | — | — | — | — | — | 1 | |
| Autologous EPCs Transfected with human eNOS | — | — | — | — | — | 1 | |
| Triamcinolone Acetonide 40mg/mL | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 |
15 more active programs hidden
Next readouts
- 2020-03-05
- 2023-11-06
- 2024-07-20
- 2024-07-30
- 2025-02
- 2025-03-01
- 2025-04-17
- 2025-08-28
- 2025-11-25
- 2025-12
Top conditions
- Breast Cancer34
- Cancer20
- Venous Thromboembolism19
- Osteoarthritis15
- Cardiac Arrest12
- Hypertension10
- Surgery9
- Deep Vein Thrombosis8
Frequently asked questions about Ottawa Hospital Research Institute
- How many clinical trials does Ottawa Hospital Research Institute have on ClinicalTrials.gov?
- Ottawa Hospital Research Institute is listed as the lead sponsor on 539 clinical trials in ClinicalTrials.gov, 93 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ottawa Hospital Research Institute's trials are in Phase 3?
- 51 of Ottawa Hospital Research Institute's trials are in Phase 3, spread across 55 active drug programs.
- What therapeutic areas does Ottawa Hospital Research Institute focus on?
- Ottawa Hospital Research Institute's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Venous Thromboembolism, Osteoarthritis, Cardiac Arrest.
- When are Ottawa Hospital Research Institute's next clinical trial readouts?
- Ottawa Hospital Research Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial”, expected around 2020-03-05.